Table 3.
Comparison of the groups according to biochemical cure at each visit (P values represent comparison between groups)
| Month | Medication | High GH, high IGF-I, n (%) | Normal GH, normal IGF-I, n (%) | Normal GH, high IGF-I, n (%) | High GH, normal IGF-I, n (%) | P |
|---|---|---|---|---|---|---|
| Baseline | Lanreotide | 29 (90.6) | 0 | 3 (9.4) | 0 | 0.199 |
| Octreotide | 31 (86.1) | 0 | 1 (2.8) | 4 (11.1) | ||
| 3 | Lanreotide | 28 (87.5) | 1 (3.1) | 3 (9.4) | 0 | 0.183 |
| Octreotide | 30 (83.3) | 1 (2.8) | 1 (2.8) | 4 (11.1) | ||
| 6 | Lanreotide | 19 (59.4) | 5 (15.6) | 4 (12.5) | 4 (12.5) | 0.739 |
| Octreotide | 19 (52.8) | 6 (16.7) | 8 (22.2) | 3 (8.3) | ||
| 12 | Lanreotide | 8 (25.0) | 17 (53.1) | 5 (15.6) | 2 (6.3) | 0.152 |
| Octreotide | 16 (44.4) | 16 (44.4) | 1 (2.8) | 3 (8.3) | ||
| 18 | Lanreotide | 7 (21.9) | 25 (78.1) | 0 | 0 | 0.454 |
| Octreotide | 11 (30.6) | 23 (63.9) | 1 (2.8) | 1 (2.8) |
GH growth hormone, IGF-I insulin-like growth factor I